Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hashem Koohy, Associate Professor of Systems Immunology, has been awarded funding from Wellcome to develop computational strategies to decipher the underlying rules of adaptive T cell immunity.

The prestigious Discovery Awards scheme from global charitable foundation Wellcome provides funding for researchers pursuing bold and creative research ideas to deliver significant shifts in understanding related to human life, health and wellbeing. 

Professor Hashem Koohy leads a systems immunology research group in the MRC Translational Immune Discovery Unit (TIDU) at the University of Oxford. His research sits at the intersection of T cell immunology and artificial intelligence, developing new machine learning tools and utilising existing technologies to decode the fundamental principles of adaptive T cell immunity.

T cells are a type of white blood cell with a crucial role in our adaptive immune system, identifying and eliminating potential threats such as viruses or cancer cells. However, sometimes T cells mistakenly attack the body's own healthy tissues and cells – a pattern commonly seen in autoimmune diseases.

T cell responses are triggered when T cells interact with target antigens. The ability to computationally map T cells to their target antigens holds enormous potential for personalised precision medicine, but this capability remains a significant scientific challenge.

In this Wellcome-funded project, Koohy's group will collaborate with the University of Cambridge and the University of Bristol to identify target self-antigens for regulatory T cells (Tregs) – a specialised subpopulation responsible for maintaining immune balance. The team will focus on understanding how Tregs contribute to the autoimmune "friendly fire" that occurs in Multiple Sclerosis (MS). The ultimate goal is to provide new insights into MS development and identify more effective treatments and prevention strategies.

Professor Koohy said:

Computational identification of self-antigen triggers of Tregs in MS represents a critical step toward understanding the drivers and development of this devastating disease.

This knowledge will be essential for clinical applications and drug discovery for treatment and other interventions. The insights we generate will also be transferable to other diseases and contexts. This funding reflects the importance of multidisciplinary collaborative projects in tackling serious human health challenges.

See more details about the award on Wellcome's website: Decoding the targets of brain regulatory T cells

Recent stories

Immune sensor can detect viral infection by monitoring cell’s own RNA

A recent study by the Rehwinkel Group and collaborators reveals a new way the immune sensor MDA5 can recognise viral infection – not only through viral RNA, but by monitoring changes to the cell’s own RNA processing.

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

MRC WIMM researchers win Health x AI Hackathon with tool to tackle delays in patient care

Three MRC WIMM researchers have won a £5,000 prize at a Health x AI Hackathon held at Google’s London headquarters, after developing an AI-powered tool designed to identify delays in patient care.

Expanding OxCITE: New funding to accelerate immunotherapy research

New funding from Cancer Research Horizons will help researchers to better understand why some patients respond well to immunotherapy while others do not.

Professor Marella de Bruijn receives MRC Programme Award

Congratulations to Professor de Bruijn, who has been awarded funding from the UKRI Medical Research Council to investigate how the first blood stem cells formed in the embryo acquire their exceptional regenerative potential, with the aim of informing future stem cell therapies.